|View printer-friendly version|
|CryoLife Announces Sale of ProCol® Distribution Rights and Purchase Option to LeMaitre Vascular, Inc.|
Mr. Mackin added, "We believe this transaction represents a positive opportunity for both companies. ProCol is a unique product within the dialysis continuum of care for those patients who had a failed synthetic graft. LeMaitre has a complementary portfolio of vascular access and dialysis related products, with corresponding customer relationships, putting them in a strong position to broaden ProCol access for patients undergoing hemodialysis."
Under the terms of the agreements,
Headquartered in suburban
Statements made in this press release that look forward in time or that express management's beliefs, expectations, or hopes are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements reflect the views of management at the time such statements are made. These statements include those regarding expanded sales opportunities for
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/cryolife-announces-sale-of-procol-distribution-rights-and-purchase-option-to-lemaitre-vascular-inc-300238323.html